The Group announced the completion of works and the finalisation of a new production area at the Settimo site, with plants for the industrial-scale production of proteins from alternative sources. On the global market, alternative proteins are used in numerous product categories that are of non-animal and non-vegetable origin – including, among others, food and beverages – and are therefore highly sustainable and have low environmental impact. The new area, worth 70 million euros, has been officially inaugurated.
“It is the biotechnology cluster in which we are investing to develop the innovative and sustainable approaches we apply for producing active ingredients, enzymes, proteins, and peptides for innovative applications in health and nutrition. Today, sustainability is key; the Olon Group has long been walking this path by adopting an integrated and global approach to reducing environmental impact by applying innovative and highly sustainable processes”, Maurizio Sartorato, VP Olon Biotech, explained.
The company has recently formalised a massive investment plan to expand and upgrade its facilities, where active ingredients are produced through advanced, low-environmental-impact biotechnological processes. The plan generates a strong positive impact on the local fabric in terms of industrial innovation, skilled and youth employment in the area, and environmental sustainability.
“We have high expectations of this important new area. The new plants, just completed and ready to start production, allow us to significantly increase our contract manufacturing capacity for alternative proteins and enzymes, which are products with a high potential as they can revolutionise the global FMCG market”, Andrea Conforto, VP Olon Biotech for CDMO, commented.
Olon Biotech, a division of Olon, focuses on biotechnological processes and offers Contract Development and Manufacturing Services (CDMO), as well as developing, manufacturing and selling Proprietary Products (PP) supporting customer companies in a wide range of industries, focusing on health & pharma, food, cosmetics, F&F and many others
